Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 6/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8679315 | 0.91 | GAA (0.54) | ESR1KMT2AMEN1CA1CA2 | |
| SCHEMBL1268976 | 0.91 | MAPT (0.53) | ESR1KMT2AMEN1CA12CA1 | |
| SCHEMBL557321 | 0.89 | MAPT (0.51) | KMT2AMEN1CA1CA2LMNA | |
| SCHEMBL2332040 | 0.89 | TDP1 (0.57) | ESR1KMT2ACA12CA1CA2 | |
| SCHEMBL8477122 | 0.89 | CA1 (0.57) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL23748867 | 0.89 | KMT2A (0.52) | ESR1KMT2AMEN1CA12CA1 | |
| SCHEMBL557186 | 0.88 | TDP1 (0.63) | KMT2ALMNACYP1A2TDP1TSHR | |
| SCHEMBL28147949 | 0.87 | ALDH1A1 (0.55) | ESR1KMT2AMEN1CA12CA1 | |
| Hydrochloric Acid SCHEMBL8460879 | 0.86 | TDP1 (0.61) | KMT2ALMNACYP1A2TDP1TSHR | |
| SCHEMBL11451991 | 0.85 | MAPK1 (0.40) | ESR1KMT2AMEN1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633335-B2 | Retinoid prodrug compound | Research Founation Itsuu Laboratory (JP) | 2014-01-21 | — | — | US | disclosed |
| CN-102336717-B | Quinazoline derivatives | EISAI R&D MAN CO LTD | 2013-09-18 | — | — | CN | disclosed |
| US-8492088-B2 | Engineering enzymes through genetic selection | GEORGIA TECH RESEARCH CORPORATION (US) | 2013-07-23 | — | — | US | disclosed |
| CN-101687819-B | External preparation | EISAI R&D MAN CO LTD | 2013-03-20 | — | — | CN | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| CN-102532041-A | Process for producing quinazoline derivative | EISAI R&D MAN CO LTD | 2012-07-04 | — | — | CN | disclosed |
| CN-102336717-A | Quinazoline derivatives | EISAI R&D MAN CO LTD | 2012-02-01 | — | — | CN | disclosed |
| US-7894118-B2 | Electrochromic compound, electrochromic composition and display device | RICOH COMPANY, LTD. (JP) | 2011-02-22 | — | — | US | disclosed |
| US-20110027820-A1 | ENGINEERING ENZYMES THROUGH GENETIC SELECTION | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-02-03 | — | — | US | disclosed |
| US-20100286427-A1 | RETINOID PRODRUG COMPOUND | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20090231663-A1 | ELECTROCHROMIC COMPOUND, ELECTROCHROMIC COMPOSITION AND DISPLAY DEVICE | RICOH COMPANY, LTD. (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-2100938-A1 | Electrochromic compound, electrochromic composition and display device | Ricoh Company, Limited (JP) | 2009-09-16 | — | — | EP | disclosed |
| US-7576135-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-20070298414-A1 | Engineering Enzymes Through Genetic Selection | GEORGIA TECH RESEARCH CORPORATION | 2007-12-27 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| WO-2005049804-A2 | ENGINEERING ENZYMES THROUGH GENETIC SELECTION | GEORGIA TECH RESEARCH CORPORATION (US) | 2005-06-02 | — | — | WO | disclosed |
| EP-0095698-B1 | PROCESS FOR THE PREPARATION OF TEREPHTHALIC AND ISOPHTHALIC ACID DICHLORIDE | BAYER AG (DE) | 1985-09-04 | — | — | EP | disclosed |
| US-4528146-A | Process for the preparation of terephthaloyl and isophthaloyl dichlorides | BAYER AKTIENGESELLSCHAFT (DE) | 1985-07-09 | — | — | US | disclosed |
| EP-0095698-A1 | Process for the preparation of terephthalic and isophthalic acid dichloride | BAYER AG (DE) | 1983-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286427-A1 | RETINOID PRODRUG COMPOUND | STRA6, RXRA, RXRB | ESR1 1295/4885KMT2A 3788/4885MEN1 2537/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | ESR1 1139/4885KMT2A 3495/4885MEN1 726/4885 |
| US-20090231663-A1 | ELECTROCHROMIC COMPOUND, ELECTROCHROMIC COMPOSITION AND DISPLAY DEVICE | TYR, AHR, ECH1 | ESR1 45/4885KMT2A 1016/4885MEN1 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.